Can a tablet Eye-Tracker replace the Neurologist's exam for MS?

NCT ID NCT06256731

Completed Diagnosis Sponsor: Innodem Neurosciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a tablet-based eye-tracking device (ETNA-MS) can accurately estimate disability levels in people with Multiple Sclerosis. Sixty adults with MS took eye-tracking tests, and the device's estimates were compared to standard neurologist assessments. The goal is to see if this simple, quick test can reliably monitor disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eye-tracking device (ETNA-MS)
What this could lead to: If successful, this device could offer a quick, objective way to monitor MS disability without needing a full in-person neurologist exam.
What could go wrong: This is a small, completed validation study with 60 people. The device may not be accurate enough for all patients or settings, and it only estimates disability, not treat it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

MS Integrated Center

Phoenix, Arizona, 85018, United States
Memorial Healthcare

Owosso, Michigan, 48867, United States
Michigan Institute for Neurological Disorders

Farmington Hills, Michigan, 48334, United States
Premier Neurology Research, P.C.

Greenville, South Carolina, 29605, United States
Rocky Mountain MS Research Group

Salt Lake City, Utah, 84103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.